Micromegakaryocytes in Human Bone Marrow

Wiesneth, Markus; Pflieger, H; Kubanek, B; Heimpel, Hermann

doi:10.1159/000207213

Cited by 30 publications

(6 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Promyelocytes are estimated to be 15–20 μm in diameter . By this criterion, small numbers of micromegakaryocytes were present in smears without anticoagulant in most of our subjects, which is in agreement with previous observations that small numbers of micromegakaryocytes may be found in BM smears of some patients without hematological diseases and in apparently healthy individuals .…”

Section: Discussionsupporting

confidence: 92%

Excessive EDTA induces morphologic changes in bone marrow smears that mimic specific features of dysplasia

Lee

Weyden

Mayson

et al. 2012

Int J Lab Hematology

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 92%

Excessive EDTA induces morphologic changes in bone marrow smears that mimic specific features of dysplasia

Lee

Weyden

Mayson

et al. 2012

Int J Lab Hematology

View full text Add to dashboard Cite

show abstract

“…Though the morphological abnormalities of megakaryocytes have been reported in AML (19), preleukaemia (7, 20, 21) and in myeloproliferative disorders (22, 23), our study demonstrated a higher frequency of abnormal megakaryocytes in patients with AML and MDS than was observed previously.…”

Section: Discussioncontrasting

confidence: 75%

Immunocytochemical detection of normal and abnormal megakaryocytes using monoclonal antibody to glycoprotein IIb‐IIIa (TP80): The quantitative assay in normal and in leukaemic patients

Satô

Shichishima

Kimura

et al. 1986

Scandinavian Journal of Haematology

View full text Add to dashboard Cite

We identified bone marrow megakaryocytes by an immunocytochemical technique using a monoclonal antibody (TP80) against platelet glycoprotein IIb‐IIIa (GPIIb‐IIIa). The immunocytochemical technique using TP80, specific to megakaryocytes, enabled us to observe cellular morphology and immunological reaction under light microscopy, and permitted quantitative assessment of megakaryocytes. In normal marrow, TP80 labelled 22 ± 5 megakaryocytes / 104 mononuclear cells (mean ± 1 SD, n = 14). In addition to typical large megakaryocytes, small immature megakaryocytes (≤ 20 μm) were recognized in 10–15% of total megakaryocytes. 4 out of 18 patients with acute myeloblastic leukaemia and 9 of 10 patients with myelodysplastic syndrome showed increased numbers of megakaryocytes. In these patients, cell size distribution was abnormal, i.e., most of the megakaryocytes consisted of small, atypical megakaryocytes. None of the patients with acute lymphoblastic leukaemia showed increased megakaryocytes. Immunocytochemical identification of megakaryocytes using a specific antibody is useful to quantitate the megakaryocytes and to detect the proliferation of atypical megakaryocytes in several leukaemic conditions.

show abstract

“…Micromegakaryocytes, fully mature MK with low ploidy, are usually seen in leukaemic and preleukemic bone marrow 36 . However, Muhury et al 37 report the presence of micromegakaryocytes in 42% of patients with immune thrombocytopenia and propose it as a marker of disturbed MK ploidization and maturation.…”

Section: Discussionmentioning

confidence: 99%

Accelerated death of megakaryocytes from Wiskott–Aldrich syndrome patients

et al. 2023

View full text Add to dashboard Cite

Summary Wiskott–Aldrich syndrome (WAS) is an X‐linked recessive disorder caused by WAS gene mutations resulting in haematopoietic/immune cell defects. Recent studies report accelerated death of WAS platelets and lymphocytes. Data on megakaryocyte (MK) maturation, viability and their possible role in thrombocytopenia development in WAS are limited. In this study we evaluate the MK viability and morphology in untreated, romiplostim‐treated WAS patients compared with normal controls. The study included 32 WAS patients and 17 healthy donors. MKs were captured from bone marrow aspirates by surface‐immobilized anti‐GPIIb‐IIIa antibody. Viability (by phosphatidylserine [PS] externalization), distribution by maturation stages and size of MK were determined by light microscopy. MK distribution by maturation stages in patients differed from controls. 40 ± 22% of WAS MKs versus 23 ± 11% of normal MKs were at maturation stage 3 (p = 0.02), whereas 24 ± 20% in WAS and 39 ± 14% in controls had megakaryoblast morphology (p = 0.05). Romiplostim treatment changed the MK maturation stages distribution close to normal. PS‐positive (PS+) MK in WAS was significantly higher (21 ± 21%) than in healthy controls (2 ± 4%, p < 0.01). WAS patients with more damaging truncating mutations and higher disease score had higher PS+ MK fraction (Spearman r = 0.6, p < 0.003). We conclude that WAS MKs have increased cell death tendency and changes in maturation pattern. Both could contribute to thrombocytopenia in WAS patients.

show abstract

Micromegakaryocytes in Human Bone Marrow

Cited by 30 publications

References 6 publications

Excessive EDTA induces morphologic changes in bone marrow smears that mimic specific features of dysplasia

Excessive EDTA induces morphologic changes in bone marrow smears that mimic specific features of dysplasia

Immunocytochemical detection of normal and abnormal megakaryocytes using monoclonal antibody to glycoprotein IIb‐IIIa (TP80): The quantitative assay in normal and in leukaemic patients

Accelerated death of megakaryocytes from Wiskott–Aldrich syndrome patients

Contact Info

Product

Resources

About